Clinical Trial Update: LMT503 First-in-human SAD, MAD, and FE Study [Phase 1]

View source ↗

Summary

Lmito Therapeutics reports a first-in-human Phase 1 study of LMT503 evaluating SAD, MAD, and single-dose escalation; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• LMT503 (LMT503)

Snippet

Sponsor: Lmito Therapeutics Inc. | Conditions: Inflammatory Bowel Disease, Colitis, Ulcerative | Phase 1 | Status: NOT_YET_RECRUITING